Menu Search
Equities

Oxford Biodynamics PLC

LMQ:DEU

Oxford Biodynamics PLC

Actions
  • Price (EUR)0.091
  • Today's Change0.001 / 1.11%
  • Shares traded0.00
  • 1 Year change-48.88%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

  • Revenue in GBP (TTM)510.00k
  • Net income in GBP-10.83m
  • Incorporated2007
  • Employees45.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.